UNSPSC 51102841: Colistin/hydrocortisone/neomycin/thonzonium

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT250. This VA Drug Class (OT250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OTIC.

UNSPSC 51102841 Colistin/hydrocortisone/neomycin/thonzonium is a Commodity code that nominally describes a single pharmaceutical formulation, but the recent state and local opportunities tagged to it show marked misalignment with the code's specification. The four most recent solicitations include a Seminole County naloxone and drug deactivation systems procurement, a Texas HHS Commission request for information on direct-to-manufacturer prescription programs, a Tampa Fire Department medical and first aid supplies bid, and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) contract for generic multi-source pharmaceuticals and over-the-counter products. None of these opportunities explicitly solicits the colistin/hydrocortisone/neomycin/thonzonium formulation itself; instead, they cast much broader nets for pharmaceutical and medical supply categories, suggesting that the code's tagging may reflect administrative or system-level categorization rather than accurate commodity matching. Issuing bodies include county health departments (Seminole County, Florida), state agencies (Texas HHS Commission), municipal fire departments (City of Tampa), and regional cooperative purchasing consortia (MMCAP, spanning Minnesota, Oregon, and participating jurisdictions). The code shows little relevant recent activity when measured against its stated pharmaceutical formulation.

Geographic activity centers on Texas (state HHS RFI), Florida (Seminole County), and the Upper Midwest through MMCAP's multistate vehicle. The Tampa Fire Department bid for medical and first aid supplies, IFB 26P00145, is designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount and an estimated contract value of $700,000, with sealed-bid due date of March 13, 2026. The MMCAP RFP (S1070000015802) for generic pharmaceuticals and OTC products, administered by Minnesota Department of Administration, has a response deadline of March 26, 2026, and establishes contracts effective July 1, 2026, with evaluation weighted 75 percent on price competitiveness and 25 percent on compliance, EDI capability, administrative fee agreement, and fixed pricing. Given the mismatch between the code's nominal scope and the breadth of actual procurement activity, this code does not reliably predict pharmaceutical formulation purchasing patterns in state and local markets.